Immunovant IMVT
NASDAQ IMVT
$35.71 +0.56 (+1.59%)
At close: Nov 10, 2026 · 4:00 PM EST

Immunovant (IMVT) Non Operating Interest Expenses (2019)

Updated

Immunovant's Non Operating Interest Expenses was $625,000 in FY2020 (year ended Mar 31, 2020).

Analysis

Immunovant (IMVT) Non Operating Interest Expenses (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 217.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 269.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Immunovant 7.38 Bn 3.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 376,000.00
Sep 30, 2019 249,000.00
API Access

Immunovant Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=IMVT&period=max&api_key=YOUR_API_KEY